NYSEAMERICAN:NNVCNanoViricides Stock Price, Forecast & News

NanoViricides is scheduled to release its next quarterly earnings announcement on Wednesday, June 10th 2020. View our earnings forecast for NanoViricides.

NanoViricides Inc (NYSEAMERICAN:NNVC) posted its quarterly earnings results on Tuesday, February, 19th. The company reported ($0.68) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.08. View NanoViricides' earnings history.

NanoViricides's stock reverse split before market open on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of NanoViricides stock prior to the reverse split would have 5 shares after the split.

Media stories about NNVC stock have trended extremely negative on Friday, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NanoViricides earned a news sentiment score of -5.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutNanoViricides.

NanoViricides saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 327,000 shares, a drop of 5.8% from the April 30th total of 347,000 shares. Based on an average daily trading volume, of 1,690,000 shares, the short-interest ratio is presently 0.2 days. Approximately 5.2% of the shares of the company are sold short. View NanoViricides' Current Options Chain.

Some companies that are related to NanoViricides include Eco Animal Health Group (EAH), Allergy Therapeutics (AGY), Trilogy International Partners (TRL), Recce Pharmaceuticals (RCE), Futura Medical (FUM), Vita Life Sciences (VLS), Pharmaxis (PXS), Avivagen (VIV), Antisense Therapeutics (ANP), China Pharma (CPHI), Sareum (SAR), Patrys (PAB), Cathay International (CTI), N4 Pharma (N4P) and Bayer (BAYN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), Micron Technology (MU), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Domino's Pizza (DPZ), AbbVie (ABBV), Novavax (NVAX), Vaxart (VXRT) and NVIDIA (NVDA).

NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."

NanoViricides' stock is owned by many different retail and institutional investors. Top institutional investors include Morgan Stanley (0.63%), Harvest Investment Services LLC (0.26%), Wedbush Securities Inc. (0.14%) and UBS Group AG (0.06%). View institutional ownership trends for NanoViricides.

NNVC stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Harvest Investment Services LLC, Wedbush Securities Inc., and UBS Group AG. View insider buying and selling activity for NanoViricides.

Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NNVC stock can currently be purchased for approximately $7.15.

NanoViricides has a market capitalization of $52.97 million. NanoViricides employs 7 workers across the globe.

The official website for NanoViricides is www.nanoviricides.com.

NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The company can be reached via phone at +1-203-9376137.